Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial
Enrolling by invitationOBSERVATIONAL
Enrollment
787
Participants
Timeline
Start Date
May 1, 2024
Primary Completion Date
May 31, 2025
Study Completion Date
May 31, 2025
Conditions
Chronic Myeloid Leukemia (CML)
Interventions
DRUG
Imatinib (STI571)
Imatinib-based regimen
Trial Locations (1)
86021
CHU de Poitiers, Poitiers
All Listed Sponsors
lead
Poitiers University Hospital
OTHER
NCT06646978 - Long-term Risk of Second Primary Malignancies for Chronic Myeloid Leukaemia in the French Imatinib-based SPIRIT Trial | Biotech Hunter | Biotech Hunter